Atrophic condition in the vagina and lower parts of the urethral tract are common in elderly women. From population based surveys it has been estimated that 40% or more of women over 60 complain of insufficient control of micturation. In ad…
Danazol, a weakly androgenic, heterocyclic compound with anabolic properties, is used primarily in the treatment of endometriosis and other gynecological complaints. Early reports indicated that the drug had little effect on plasma lipid (c…
The American Fertility Society (AFS) classification for endometriosis is a widely-used system for categorizing the severity of pelvic endometriosis. Although this classification represents a detailed description of the location and extent o…
The non-surgical treatment of endometriosis involves hormone therapy that either affects the lesions directly, or indirectly inhibits endometrial proliferation and induces atrophy through estrogen deprivation, or through a combination of th…
The current management of endometriosis includes expectant, medical, surgical and combined therapies and the selection is based on the staging of the disease proposed by the American Fertility Society (AFS). This approach, however, has prov…
It is well recognized that cell-mediated immune responses contribute to the elimination of foreign antigens and cells from the invading organism. It is also likely that the immune system can recognize and eliminate altered or misplaced auto…
In many ways endometriosis represents yet another form of unexplained infertility. The disease is clearly associated with a decrease in fecundity and while in advanced stages of the condition this infertility can be attributed to tubal fact…
CA 125 is an antigenic determinant on a high molecular weight glycoprotein. A monoclonal antibody has been produced which recognizes this, and allows us to measure the expression of CA 125 in serum. Tissue distribution of the CA 125 determi…
Piroxicam, a potent inhibitor of prostaglandins, is effective and well-tolerated in the treatment of primary dysmenorrhea. A single 40 mg dose has been shown to rapidly reduce the uterine hypercontractility of primary dysmenorrhea. In clini…
Serum levels of sex hormone binding globulin (SHBG) were measured by radioelectro-immunoassay before and during administration of danazol in daily doses varying between 200 and 800 mg for a period of 1-6 months. The patients consisted of di…
Concentrations of cytosol estrogen (ERc) and progestin (PRc) receptors and the activities of 17 beta-hydroxysteroid dehydrogenase (17-HSD) were measured in 80 untreated and 23 danazol-treated endometriotic tissue specimens. The results were…
The purpose of the investigation was to study various aspects of danazol treatment in patients with fibrocystic breast disease and pronounced mastodynia. To qualify for inclusion, the patients in this study had to have a mammographically co…
Previous studies have demonstrated a hereditary tendency to develop endometriosis and the incidence of the disease varies in different ethnic groups. The genetic background to these differences has not been clearly explained. The present in…
The antigonadotropic action of danazol is still a subject of controversy. Danazol does not cause a consistent and significant suppression of basal gonadotropin concentrations in premenopausal women. In order to investigate the possible effe…
During treatment with danazol the serum concentration of thyroxin-binding globulin (TBG) decreases. This effect is probably a direct effect on TBG production at the cellular level. In order to exclude an indirect effect on TBG production vi…
A histochemical method for the detection of steroid-binding sites in very small tissue specimens was evaluated. Competitive binding experiments proved the method to be sufficiently specific. When applied to endometrium and endometriotic tis…
The influence of danazol treatment on uterine activity was studied by means of repeated intra-uterine pressure recordings in two women with laparoscopically diagnosed endometriosis. During a control cycle the women had normal plasma levels …